Background Artemether-lumefantrine (AL) is a major and highly effective artemisinin-based
combination therapy that is becoming increasingly important as a new first-line therapy …

Artemisinin derivative–based combination therapy is expected to suppress the development
of Plasmodium falciparum drug resistance in Africa. We have performed an artemether …

Adequate clinical and parasitologic cure by artemisinin combination therapies relies on the
artemisinin component and the partner drug. Polymorphisms in the Plasmodium falciparum …

Plasmodium falciparum response mechanisms to the major artemisinin-based combination
therapies (ACTs) are largely unknown. Multidrug-resistance protein (MRP)–like adenosine …

The global dissemination of drug-resistant Plasmodium falciparum is spurring intense efforts
to implement artemisinin (ART)–based combination therapies for malaria, including …

Artemisinin partial resistance may facilitate selection of Plasmodium falciparum resistant to
combination therapy partner drugs. We evaluated 99 P. falciparum isolates collected in 2021 …

ABSTRACT Artemether-lumefantrine (AL), dihydroartemisinin-piperaquine (DP), and
amodiaquine-sulfadoxine-pyrimethamine (AQ-SP) offer excellent antimalarial efficacy but …

Antimalarial drug resistance has threatened global malaria control since chloroquine (CQ)-
resistant Plasmodium falciparum emerged in Asia in the 1950s. Understanding the impacts …

Artemether–lumefantrine (AL) became the first-line treatment for uncomplicated malaria in
Kenya in 2006. Studies have shown AL selects for SNPs in pfcrt and pfmdr1 genes in …

Summary Objective Artemether‐lumefantrine (AL), presently the most favoured combination
therapy against uncomplicated Plasmodium falciparum malaria in Africa, has recently shown …